KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Expansion Plans 8-K Filing 2025 - Product Expansion On June 5, 2025, Kiniksa Pharmaceuticals announced that their KPL-387 Phase 2/3 clinical trial for recurrent pericarditis is set to start in mid-2025, with Phase 2 results anticipated in the second half of 2026. An investor presentation was also made available on their website.Get access to all SEC 8-K filings of the KINIKSA PHARMACEUTICALS INTERNATIONAL PLC